These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 30730615)

  • 1. A Cocktail Interaction Study Evaluating the Drug-Drug Interaction Potential of the Perpetrator Drug ASP8477 at Multiple Ascending Dose Levels.
    Treijtel N; Collins C; van Bruijnsvoort M; Fuhr R; Ernault E; Gangaram-Panday S; Passier P
    Clin Pharmacol Drug Dev; 2019 May; 8(4):529-540. PubMed ID: 30730615
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
    Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
    Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
    Wang J; Zhang ZY; Lu S; Powers D; Kansra V; Wang X
    Support Care Cancer; 2019 Mar; 27(3):819-827. PubMed ID: 30084103
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Mutual Drug-Drug Interaction within Geneva Cocktail for Cytochrome P450 Phenotyping using Innovative Dried Blood Sampling Method.
    Bosilkovska M; Samer C; Déglon J; Thomas A; Walder B; Desmeules J; Daali Y
    Basic Clin Pharmacol Toxicol; 2016 Sep; 119(3):284-90. PubMed ID: 27009433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
    Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
    Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of fermented red ginseng on cytochrome P450 and P-glycoprotein activity in healthy subjects, as evaluated using the cocktail approach.
    Kim MG; Kim Y; Jeon JY; Kim DS
    Br J Clin Pharmacol; 2016 Dec; 82(6):1580-1590. PubMed ID: 27495955
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of the "Inje cocktail" for high-throughput evaluation of five human cytochrome P450 isoforms in vivo.
    Ryu JY; Song IS; Sunwoo YE; Shon JH; Liu KH; Cha IJ; Shin JG
    Clin Pharmacol Ther; 2007 Nov; 82(5):531-40. PubMed ID: 17392720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LC-MS/MS analysis of the plasma concentrations of a cocktail of 5 cytochrome P450 and P-glycoprotein probe substrates and their metabolites using subtherapeutic doses.
    Cusinato DAC; Filgueira GCO; Rocha A; Cintra MACT; Lanchote VL; Coelho EB
    J Pharm Biomed Anal; 2019 Feb; 164():430-441. PubMed ID: 30445356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
    Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
    Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
    Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
    J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
    Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
    Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Comprehensive In Vivo and In Vitro Assessment of the Drug Interaction Potential of Red Ginseng.
    Seong SJ; Kang WY; Heo JK; Jo J; Choi WG; Liu KH; Lee S; Choi MK; Han YH; Lee HS; Ohk B; Lee HW; Song IS; Yoon YR
    Clin Ther; 2018 Aug; 40(8):1322-1337. PubMed ID: 30078466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
    Pai SM; Yamada H; Murata H
    Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Assessment of CYP-Mediated Drug Interactions for Enasidenib Based on a Cocktail Study in Patients with Relapse or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome.
    Cheng Y; Wang X; Ghosh A; Pu J; Carayannopoulos LN; Li Y
    J Clin Pharmacol; 2024 Aug; 64(8):984-992. PubMed ID: 38563070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy Volunteers.
    Rohr BS; Krohmer E; Foerster KI; Burhenne J; Schulz M; Blank A; Mikus G; Haefeli WE
    Clin Pharmacokinet; 2024 Apr; 63(4):469-481. PubMed ID: 38393578
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of modafinil as a perpetrator of metabolic drug-drug interactions using a model informed cocktail reaction phenotyping trial protocol.
    Rowland A; van Dyk M; Warncken D; Mangoni AA; Sorich MJ; Rowland A
    Br J Clin Pharmacol; 2018 Mar; 84(3):501-509. PubMed ID: 29178272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of effects of repeated oral doses of fedratinib on inhibition of cytochrome P450 activities in patients with solid tumors using a cocktail approach.
    Ogasawara K; LoRusso PM; Olszanski AJ; Rixe O; Xu C; Yin J; Palmisano M; Krishna G
    Cancer Chemother Pharmacol; 2020 Jul; 86(1):87-95. PubMed ID: 32537715
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of nivasorexant (ACT-539313), a selective orexin-1-receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects.
    Berger B; Kaufmann P; Berse M; Treiber A; Grignaschi N; Dingemanse J
    Pharmacol Res Perspect; 2023 Oct; 11(5):e01143. PubMed ID: 37800597
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail".
    Chainuvati S; Nafziger AN; Leeder JS; Gaedigk A; Kearns GL; Sellers E; Zhang Y; Kashuba AD; Rowland E; Bertino JS
    Clin Pharmacol Ther; 2003 Nov; 74(5):437-47. PubMed ID: 14586384
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of SHR0302 on the pharmacokinetics of CYP3A4, CYP2C8, CYP2C9 and CYP2C19 probe substrates in healthy volunteers: A cocktail analysis.
    Fu M; Luo L; Feng S; Lin H; Lu Z; Gu F; Fan Y; Wu B; Huang J; Shen K
    Br J Clin Pharmacol; 2023 Dec; 89(12):3659-3668. PubMed ID: 37464978
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.